Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Aumolertinib→

Aumolertinib PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
1899921-05-1
Molecular formula
C30H35N7O2
Molecular weight
525.6 g/mol
Drug class
Third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitortargeted antineoplastic
Mechanism of action
Selectively and irreversibly inhibits mutant EGFR, including sensitising mutations and T790M resistance mutation, reducing downstream oncogenic signalling in EGFR-mutated tumour cells.
Indications / reported uses
  • Treatment of locally advanced or metastatic EGFR-mutated non-small-cell lung cancer (NSCLC) in China and other jurisdictions where aumolertinib is authorised; treatment line and mutation criteria are product- and jurisdiction-specific

Sources: PubMed — Aumolertinib clinical pharmacology and NSCLC · NLM MeSH — Aumolertinib · FDA product information

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor; targeted antineoplastic

Mechanism of action

Selectively and irreversibly inhibits mutant EGFR, including sensitising mutations and T790M resistance mutation, reducing downstream oncogenic signalling in EGFR-mutated tumour cells.

General use cases

  • Treatment of locally advanced or metastatic EGFR-mutated non-small-cell lung cancer (NSCLC) in China and other jurisdictions where aumolertinib is authorised; treatment line and mutation criteria are product- and jurisdiction-specific

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Aumolertinib PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Aumolertinib Permitted Daily Exposure (PDE) report (the Aumolertinib PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Aumolertinib Occupational Exposure Limit (OEL) report (the Aumolertinib OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.